Ariel Berger, Nicola Sawalhi-Leckenby, Gary Inglese, George Skountrianos, Paolo Pigatto
{"title":"Ceramide-Infused Skin Barrier for Use Following Ostomy Surgery: A Narrative Review of Available Data.","authors":"Ariel Berger, Nicola Sawalhi-Leckenby, Gary Inglese, George Skountrianos, Paolo Pigatto","doi":"10.1097/WON.0000000000001261","DOIUrl":null,"url":null,"abstract":"<p><p>This narrative review summarizes published data regarding a ceramide-infused skin barrier intended for use in patients who have undergone creation of a fecal or urinary ostomy (colostomy, ileostomy, urostomy). A randomized clinical trial (ADVOCATE) found that the mean total ostomy-related costs of care over a 12-week period were 14% lower among patients randomized to the ceramide-infused skin barrier than among control barriers. Study findings further suggested that the ceramide-infused skin barrier reduced the incidence of peristomal skin complications. Economic models, based in part on findings from the ADVOCATE trial, suggest that the ceramide-infused skin barrier is cost-effective versus other ostomy barriers from a per-patient perspective, and it is associated with cost savings for payers from a population perspective. Information from several studies, both randomized trials and observational studies, indicate quality-of-life benefits and relatively high levels of patient satisfaction associated with the ceramide-infused skin barrier. Collectively, available data indicate that, relative to other skin barriers, the ceramide-infused skin barrier is a cost-effective and cost-saving option that also provides quality-of-life benefits for patients who have undergone ostomy.</p>","PeriodicalId":520700,"journal":{"name":"Journal of wound, ostomy, and continence nursing : official publication of The Wound, Ostomy and Continence Nurses Society","volume":"53 2","pages":"115-123"},"PeriodicalIF":1.8000,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12947920/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of wound, ostomy, and continence nursing : official publication of The Wound, Ostomy and Continence Nurses Society","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/WON.0000000000001261","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/2/27 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
This narrative review summarizes published data regarding a ceramide-infused skin barrier intended for use in patients who have undergone creation of a fecal or urinary ostomy (colostomy, ileostomy, urostomy). A randomized clinical trial (ADVOCATE) found that the mean total ostomy-related costs of care over a 12-week period were 14% lower among patients randomized to the ceramide-infused skin barrier than among control barriers. Study findings further suggested that the ceramide-infused skin barrier reduced the incidence of peristomal skin complications. Economic models, based in part on findings from the ADVOCATE trial, suggest that the ceramide-infused skin barrier is cost-effective versus other ostomy barriers from a per-patient perspective, and it is associated with cost savings for payers from a population perspective. Information from several studies, both randomized trials and observational studies, indicate quality-of-life benefits and relatively high levels of patient satisfaction associated with the ceramide-infused skin barrier. Collectively, available data indicate that, relative to other skin barriers, the ceramide-infused skin barrier is a cost-effective and cost-saving option that also provides quality-of-life benefits for patients who have undergone ostomy.